Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 1...
December 04 2017 - 4:05PM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
company focused on helping improve patient lives by providing high
quality biologics manufacturing services to biotechnology and
pharmaceutical companies, today announced that it will report
financial results for the second quarter of fiscal year 2018 ended
October 31, 2017 on December 11, 2017 after market close
and will host a conference call and webcast at 1:30 PM Pacific Time
(4:30 PM Eastern Time). Peregrine's senior management will discuss
financial results for the second quarter and review recent
corporate developments.
To listen to the live webcast, or access the
archived webcast, please visit:
http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial
(877) 312-5443 or (253) 237-1126 and request the Peregrine
Pharmaceuticals call.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a company
transitioning from an R&D focused business to a pure play
contract development and manufacturing organization (CDMO).
Peregrine's in-house CDMO services, including cGMP manufacturing
and development capabilities, are provided through its wholly-owned
subsidiary Avid Bioservices, Inc. (www.avidbio.com).
Peregrine is pursuing licensing or selling its
proprietary R&D assets, including its lead immunotherapy
candidate, bavituximab, which is currently being evaluated in
clinical trials in combination with immune stimulating therapies
for the treatment of various cancers. For more information,
please visit www.peregrineinc.com.
About Avid Bioservices, Inc. Avid
Bioservices, a wholly owned subsidiary of Peregrine
Pharmaceuticals, provides a comprehensive range of process
development, high quality cGMP clinical and commercial
manufacturing services for the biotechnology and biopharmaceutical
industries. With over 20 years of experience producing
monoclonal antibodies and recombinant proteins in batch, fed-batch
and perfusion modes, Avid's services include cGMP clinical and
commercial product manufacturing, purification, bulk packaging,
stability testing and regulatory strategy, submission and
support. The company also provides a variety of process
development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product characterization. For more
information about Avid, please visit www.avidbio.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024